Photo from academic.microsoft.com
The combination of HMG‐CoA reductase inhibitors (statins) and fluoroquinolones generally is not considered a significant risk factor for rhabdomyolysis. Rhabdomyolysis is a known risk associated with statin therapy but has… Click to show full abstract
The combination of HMG‐CoA reductase inhibitors (statins) and fluoroquinolones generally is not considered a significant risk factor for rhabdomyolysis. Rhabdomyolysis is a known risk associated with statin therapy but has seldom been described with fluoroquinolone use. We describe a case of acute rhabdomyolysis involving the co‐administration of atorvastatin and levofloxacin.
Keywords:
induced rhabdomyolysis;
rhabdomyolysis patient;
patient concurrent;
case;
rhabdomyolysis;
levofloxacin induced
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!